At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,770 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An International, Multi-centre, Non-interventional Retrospective Study to Describe Treatment Pathways, Outcomes, and Resource Use in Patients With Classical Hodgkin Lymphoma (B-HOLISTIC)
In Brief
An observational study for Classical Hodgkin Lymphoma and Relapsed or Refractory Classical Hodgkin Lymphoma. Completed, enrolled 1,770 participants across 1 site.
Detailed Summary
The purpose of this study is to describe progression-free survival (PFS) in participants with relapsed or refractory classical Hodgkin lymphoma (RRHL), defined as the time from initiation of first treatment for RRHL to first documentation of relapse or disease progression, or death.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartNov 2017
Primary CompletionOct 2019
TodayJul 2026
First PostedOct 31, 2017
Enrollment StartNov 21, 2017
Primary CompletionOct 31, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 8.7 years ago